Literature DB >> 21185550

Individualized, targeted wound treatment based on the tissue bacterial level as a biological marker.

Yvonne N Pierpont1, M Georgina Uberti, Francis Ko, Martin C Robson, Charlotte A Smith, Terry E Wright, Wyatt G Payne.   

Abstract

BACKGROUND: The use of biologic markers to aid in individualizing wound treatment may help improve outcomes. A biologic marker that has been demonstrated to be predictive of healing in both chronic and acute wounds is wound tissue bacterial level. The objective of this study was to determine whether tissue bacterial level can be used to individualize wound treatment regimens with a stem-like cell-derived product.
METHODS: Amnion-derived cellular cytokine solution (ACCS) was topically applied to rat chronic wounds, and healing rates were measured.
RESULTS: Experimental wounds treated with ACCS demonstrated accelerated healing regardless of the tissue level of bacteria, compared with saline. As the level of tissue bacteria increased, the frequency of ACCS application required to obtain optimal results increased.
CONCLUSIONS: It appears that the biologic characteristic of tissue bacterial level can serve as a marker to predict the response of open granulating wounds treated with ACCS. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21185550     DOI: 10.1016/j.amjsurg.2010.09.009

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Update in surgery.

Authors:  Gheorghe Borcean
Journal:  Maedica (Buchar)       Date:  2011-01

2.  Exploratory Phase II Multicenter, Open-Label, Clinical Trial of ST266, a Novel Secretome for Treatment of Persistent Corneal Epithelial Defects.

Authors:  Bennie H Jeng; Pedram Hamrah; Ziv Z Kirshner; Benjamin C Mendez; Howard C Wessel; Larry R Brown; David L Steed
Journal:  Transl Vis Sci Technol       Date:  2022-01-03       Impact factor: 3.283

3.  Use of amnion-derived cellular cytokine solution for the treatment of gingivitis: A 2-week safety, dose-ranging, proof-of-principle randomized trial.

Authors:  Hatice Hasturk; David Steed; Emre Tosun; Melissa Martins; Constantinos Floros; Daniel Nguyen; Danielle Stephens; Maryann Cugini; Jacqueline Starr; Thomas E Van Dyke
Journal:  J Periodontol       Date:  2021-05-06       Impact factor: 6.993

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.